A Massachusetts-based pharmaceutical company will pay $20.75 million settle a whistleblower’s allegations that the company knowingly promoted misleading instructions for a skin lesion drug that caused doctors to submit false claims to Medicare.
DUSA Pharmaceuticals, a subsidiary of Sun Pharmaceutical Industries, Inc. (Sun Pharma), allegedly convinced doctors to speed up the incubation process for the drug Levulan Kerastick, a prescription drug approved by the United States Food and Drug Administration (FDA) for the treatment skin lesions on the face or scalp.
